Inhibrx (NASDAQ:INBX) and Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Contrast

Inhibrx (NASDAQ:INBXGet Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUEGet Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Inhibrx and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inhibrx -13,408.95% -678.51% -91.73%
Monte Rosa Therapeutics N/A -74.13% -49.14%

Valuation & Earnings

This table compares Inhibrx and Monte Rosa Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inhibrx $1.63 million 520.81 -$241.36 million ($5.03) -3.23
Monte Rosa Therapeutics N/A N/A -$135.35 million ($2.52) -1.66

Monte Rosa Therapeutics has lower revenue, but higher earnings than Inhibrx. Inhibrx is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by company insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Inhibrx has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Inhibrx and Monte Rosa Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibrx 0 2 0 0 2.00
Monte Rosa Therapeutics 0 1 2 0 2.67

Inhibrx currently has a consensus target price of $27.00, indicating a potential upside of 66.26%. Monte Rosa Therapeutics has a consensus target price of $11.00, indicating a potential upside of 162.53%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Inhibrx.

Summary

Monte Rosa Therapeutics beats Inhibrx on 9 of the 13 factors compared between the two stocks.

About Inhibrx

(Get Free Report)

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.